Intradermal Rabies Immunization Using NanoJect: A Comparative Study
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The study is planned as a single-center, randomized, double-blind placebo-controlled,
comparative Phase I, first-in-man study to assess the safety and tolerability of the
NanoJect™ device, and the immunogenicity of the rabies vaccine "Vaccin rabique Pasteur®"
delivered with the NanoJect™ device by ID route.